Introduction:
Closed loop systems comprising a continuous glucose monitoring (CGM) sensor and an insulin pump interfaced via suitable control software, continue to be the most effective solution for management of Type 1 Diabetes. The effectiveness of the closed loop system is highly dependent on the accuracy of the CGM sensors. Although decades of sensor technology development have improved the mean average relative deviation of the CGM devices there are still issues with accuracy of CGM sensors in the low concentration regime. In addition, interferences due to common substances such as acetaminophen, ascorbic and uric acid remain a challenge. We address these issues through the use of minimally invasive microneedle array electrodes (Trzebinski et al., 2012; El-Laboudi et al. 2013) coupled to a glucose dehydrogenase based direct electron transfer system and is therefore less likely to be subject to interference as has been reported recently (Sekimoto et al. 2016) Method: The microneedle array electrodes are used over 24-48 hours to minimise the biofouling effect. The design of the microprobe arrays electrodes are such that the arrays are partitioned into working, reference and background compensation electrodes to enable parallel measurements of glucose and the background currents respectively. Results: Functionalisation of the microprobe arrays with glucose dehydrogenase entrapped in polyphenols yield a third generation biosensor that operates at a lower potential (400mV) than those reliant on hydrogen peroxide detection (700mV). The use of compensation electrodes and a direct electron transfer are expected to drastically reduce the effects of interference due to electro-active species.
